Edesa Biotech Inc (OQ:EDSA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 100 Spy Crt
MARKHAM ON L3R 5H6
Tel: N/A
Website: https://www.edesabiotech.com
IR: See website
<
Key People
Michael J. Brooks
President
Pardeep Nijhawan
Chief Executive Officer, Corporate Secretary, Director
Stephen Lemieux
Chief Financial Officer
Business Overview
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. It has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. It is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.
Financial Overview
For the fiscal year ended 30 September 2024, Edesa Biotech Inc revenues was not reported. Net loss decreased 26% to $6.2M. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 24% to $7M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.93 to -$1.93.
Employees: 16 as of Dec 13, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $5.12M as of Sep 30, 2024
Annual revenue (TTM): $0.00M as of Sep 30, 2024
EBITDA (TTM): -$6.83M as of Sep 30, 2024
Net annual income (TTM): -$6.17M as of Sep 30, 2024
Free cash flow (TTM): -$4.89M as of Sep 30, 2024
Net Debt Last Fiscal Year: N/A
Shares outstanding: 3,467,658 as of Dec 11, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.